VJHemOnc Podcast

Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT

Jun 25, 2024

Experts Mario Nuvolone, Vaishali Sanchorawala, and Patrick Hagen discuss the critical importance of early diagnosis in AL amyloidosis, ongoing clinical trials like Venetoclax and Exazomib, patient selection for SCT, and challenges in managing relapsed refractory amyloidosis.

08:43

Creator website

Episode guests

Mario Nuvolone, MD

Patrick Hagen, MD

Vaishali Sanchorawala, MD

AI Summary

AI Chapters

Episode notes

Podcast summary created with Snipd AI

Quick takeaways

Early diagnosis crucial in AL amyloidosis for better treatment outcomes and reduced morbidity.

Multiple clinical trials ongoing to address treatment questions, including new approaches for relapsed cases.

Deep dives

Importance of Early Diagnosis in Amyloidosis

Early diagnosis in amyloidosis is crucial as identifying the disease before advanced organ damage occurs significantly impacts treatment options and reduces morbidity. Patients with a non-monoclonal gamma apathy under hematologic follow-up should also be evaluated for potential progression towards amyloidosis. Screening for early organ involvement through biomarkers allows for presymptomatic detection and successful treatment outcomes.

Intro

2min

Discussion on Important Clinical Trials in AL Amyloidosis

3min

Patient Selection for Stem Cell Transplantation and Challenges in Relapsed Refractory Amyloidosis

4min

Welcome to today’s VJHemOnc podcast episode, where we will be sharing key highlights from the 2024 International Symposium on Amyloidosis (ISA), which was held in Rochester, MN. This podcast covers a variety of unmet needs in light chain (AL) amyloidosis, as well as emerging trials in the field.

Join leading experts Mario Nuvolone, MD, PhD, University of Pavia, Pavia, Italy, Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, Patrick Hagen, MD, Loyola University Medical Center, Chicago, IL, and Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, as they discuss the critical importance of early diagnosis in AL amyloidosis, exciting clinical trials in progress, patient selection for stem cell transplantation (SCT), and more.

The post Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT appeared first on VJHemOnc.